Compare WTO & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTO | BGMS |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | China | Malaysia |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.0M |
| IPO Year | 2019 | N/A |
| Metric | WTO | BGMS |
|---|---|---|
| Price | $3.09 | $0.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 503.4K | 147.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.74 |
| 52 Week High | $4.50 | $6.70 |
| Indicator | WTO | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 67.81 | 40.09 |
| Support Level | $0.67 | $0.74 |
| Resistance Level | $4.50 | $1.12 |
| Average True Range (ATR) | 0.50 | 0.06 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 65.26 | 24.28 |
UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.